<article id="sc_page04" class="slide" data-ag-slide-name="sc_page04">
    <div class="basic">
      <h1 data-ag-editable="Main Title">Neulasta<sup>®</sup> maintains effective neutrophil<br/>
          concentrations as long as it is needed</h1>
        <!-- Content here -->
        <div id="center-content">
            <h4 data-ag-editable="Subtitle">Breast cancer<sup>[SmPC, Green 2003]</sup></h4>
            <p id="slide-title">Median Neulasta<sup>®</sup> serum concentration and ANC in<br/>
                chemotherapy-treated patients after a single 6 mg injection</p>
        </div>
        <div id="sc_page04_graph_holder" class="main_content_style">
                <!-- GRAPG 1-->
                <div id="sc_page04_large"  class="poz_graph_1">
                    <img src="content/images/sc_page04/graph1.png" width="768" height="544" data-ag-editable="  Graph Background" />
                    <div id="sc_page04_graph_vertical_numbers">
                        <ul data-ag-editable="Graph Vertical Axis Data">
                            <li>1000</li>
                            <li>100</li>
                            <li>10</li>
                            <li>1</li>
                            <li>0.1</li>
                        </ul>
                    </div>
                    <div id="sc_page04_graph_vertical_numbers-right">
                        <ul data-ag-editable="Graph Vertical Axis Data">
                            <li>100</li>
                            <li>10</li>
                            <li>1</li>
                            <li>0.1</li>
                        </ul>
                    </div>
                    <div id="sc_page04_graph_horizontal_numbers">
                        <ul data-ag-editable=" Graph Horizontal Axis Data">
                            <li>0</li>
                            <li>3</li>
                            <li>6</li>
                            <li>9</li>
                            <li>12</li>
                            <li>15</li>
                            <li>18</li>
                            <li>21</li>
                        </ul>
                    </div>
                    <div id="sc_page04_graph_content_large">
                        <p class="graph1_vertical_axis_title_large" data-ag-editable=" Vertical Axis Title">Median serum concentration Neulasta<sup>®</sup> (ng/mL) </p>
                        <p class="graph1_horizontal_axis_title_large" data-ag-editable=" Horizontal Axis Title">Study day</p>
                        <p class="graph1_bottom_text_large" data-ag-editable=" Bottom Text">Adapted from Neulasta®, Summary of Product Characteristics and Green MD et al. Ann Oncol 2003; 14(1):29-35</p>
                        <p id="white-slogan">The residual concetration of Neulasta is likely to be negligibile for ANC ≥ 1000/mm<sup>2</sup></p>
                        <p id="legend1">Neulasta<sup>®</sup>concetration</p>
                        <p id="legend2">ANC </p>
                        <p id="legend3">A single injection of Neulasta<sup>®</sup> about 24 hours the end of chemotherapy </p>
                        <p id="legend4">Normal Range<sup>®</sup></p>
                        <p class="graph1_vertical_axis_title_large-right" data-ag-editable=" Vertical Axis Title">Median absolute neutrophil count (cells x 10<sup>9</sup>/L) </p>
                    </div>
                </div><!--END GRAPh 1-->
            </div><!-- END HOLDER GRAPH -->
        <img id="red-square" src="content/images/sc_page04/red-square.png"/>
        <p id="bottom-copy"> In cycles 2, 3, and 4, the mean depth of ANC nadir was higher for patients treated with
                lipegfilgrastim vs Neulasta® (2.6 vs 2.0, 2.5 vs 2.0, and 2.7 vs 2.3 × 109/L; p=0.0189, p=0.0353,
                and p=0.1122, respectively)<sup>[Bodarenko 2013]</sup></p>
        </div>
     </div>
    <!-- Reference Information Starts -->
    <div class="lightbox_data" id="sc_page04_refs">
       <div class="main_content_style">
          <p><strong data-ag-editable="References Title">References:</strong></p>
          <br />
          <div data-ag-editable="References List">
             <ol>
                 <li>Neulasta®, Summary of Product Characteristics</li>
                 <li>Green MD et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14(1):29-35</li>
                 <li>Kratz A et al. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Laboratory reference values. N Engl J Med 2004; 351(15):1548-1636</li>
                 <li>Bodarenko I et al. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. BMC Cancer 2013; 13:386</li>

             </ol>
          </div>
          <p data-ag-editable="References Bottom Copy"></p>
       </div>
    </div>
    <!-- Reference Information Ends -->
</article>